Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 1, 2013, Pages 50-56

  Maria, Tolia G ^a   Vasileios, Kouloulias E ^b   Panagiotis, Pantelakos S ^a   Kostas, Syrigos N ^c  

^a Medical School   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute phase proteins; Lung cancer; Radiotherapy

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL ANALYSIS;

EID: 84870334916     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced NSCLC. J Clin Oncol 2010; 28: 2181-2190.
3. O'Rourke N, Roque' I, Figuls M, Farre' Bernado', Macbeth F. Concurrent chemoradiotherapy in NSCLC. Cochrane Database Syst Rev 2010.
4. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A 3rd. Final results of phase III trial in regionally advanced unresectable NCSLC: Radiation Therapy Oncology Group. Chest 2000; 117: 358-364.
5. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97: 215-223.
6. Van Leeuwen MA, Van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol 1994; 8: 531-552.
7. Macchia V, Mariano A, Cavalcanti M, Coppa A, Cecere C, Fraioli G, Elia S, Ferrante G. Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin. Int J Biol Markers 1987; 2: 151-156.
8. Fracchia A, Ubbiali A, El Bitar O, Pacetti M, Sommariva E, Arreghini M Longhini E, Bonalumi GP. A comparative study on ferritin concentration in serum and bilateral bronchoalveolar lavage fluid of patients with peripheral lung cancer versus control subjects. Oncology 1999; 56: 181-188.
9. Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol 2010; 27: 268-277.
10. Franciolli M, Rosenmund A. Iron and ironbinding proteins in the differential diagnosis of pleural effusion. Schweiz Med Wochenschr 1989; 119: 785-790.
11. ICRU Report 50, 62: Prescribing, Recording and Reporting Photon Beam Therapy. 1993, 1999.
12. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable nonsmall cell lung cancer. Br J Cancer 2002; 87: 264-267.
13. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
14. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-3936.
15. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006; 119: 166 e117-128.
16. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable nonsmall-cell lung cancer. Br J Cancer 2003; 89: 1028-1030.
17. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host-and tumorrelated factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003; 238: 197-202.
18. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
19. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T. Elevation of preoperative serum Creactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-252.
20. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastrooesophageal cancer. Br J Cancer 2006; 94: 637-641
21. Chang-Yu Wang, Ming-Jang Hsieh, Yi-Chun Chiu, Shau-Hsuan Li, Hurng-Wern Huang, Fu-Min Fang, Yu-Jie Huang. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 2009; 92: 270-275
22. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammationbased prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886
23. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-1864
24. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, Okuda H, Kudo T. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 82: 107-110.
25. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H. Clinical implications of serum Creactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002; 99: 167-170.
26. Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006; 94: 227-230.
27. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammationbased prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-212.
28. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6: 450-453.